Cardiovascular and kidney disease are the two most common conditions present at the same time in people living with type 2 diabetes. Data on the prevalence, quality of care and outcomes of people with these inter-related conditions is not available globally.

The iCaReMe Registry aims to address this unmet need. Developed by AstraZeneca in partnership with an independent external scientific committee, iCaReMe is a real-world evidence-based international observational study that is collecting data on cardio-renal complications in people with type 2 diabetes in routine clinical settings.

iCaReMe aims to:

• Describe the characteristics of people with type 2 diabetes, heart failure and/or chronic kidney disease from clinical practices across multiple care settings and geographic regions – including those currently with limited availability of real world data.
• Evaluate quality of care, including management of risk factors and use of guideline directed therapies.
• Track long-term outcomes, including incidence of complications.
• Inform future multidisciplinary interventions with the overarching goal of improving quality of care and outcomes on a global scale.

iCaReMe provides an in-depth cloud-based registry for healthcare professionals to follow up on their patients with diabetes and cardio-renal complications. Patient data (prospective or retrospective) is uploaded to a cloud-based registry. Criteria for patient inclusion includes:

• Being over 18 years old.
• Having type 2 diabetes, heart failure and/or chronic kidney disease
• Providing written informed consent to participate in the study.

IDF supports the iCaReMe Registry and will work with AstraZeneca to:

• Promote participation in the registry of healthcare professionals in low- and middle-income countries.
• Raise awareness of the risk and potential consequences of cardio-renal complications in people living with diabetes.
• Raise awareness on the socio-economic impact of cardio-renal complications in type 2 diabetes.
• Advocate for policies to improve the prevention, detection and management of type 2 diabetes.
• Enhance education of healthcare professionals on the importance of early diagnosis of cardio-renal complications in type 2 diabetes and the need to take appropriate action.

IDF invites healthcare professionals to participate in the iCaReMe cloud-based registry. For more information on participating in the study and accessing the registry, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..